Simplified Lipid A Analog Monosaccharide Core
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for septic shock and endotoxemia are inadequate as they either fail to effectively antagonize lipopolysaccharide (LPS) signaling or activate inflammatory cascades, and there is a need for simplified Lipid A analogs that lack the complexity of the highly lipidated diphosphorylated disaccharide core yet maintain potent antagonistic activity against LPS.
Innovation Solution
Development of structurally simplified Lipid A analogs, including carbohydrate conjugates with a monosaccharide core, hydrophobic side chains, and an amino acid ionic motif, which act as antagonists to block LPS signaling without activating the inflammatory cascade, thereby inhibiting the deleterious effects of septic shock and endotoxemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Lipid A analogs with highly lipidated diphosphorylated disaccharide core are used, then potent antagonistic activity against LPS is achieved, but structural complexity increases significantly
Solution Approach 1:
The patent extracts and removes the highly lipidated diphosphorylated disaccharide core from the Lipid A structure, retaining only the essential monosaccharide core with simplified fatty acid attachments. This extraction eliminates unnecessary structural complexity while preserving the key functional elements needed for LPS receptor binding and antagonistic activity.
Solution Approach 2:
The patent applies local quality by selectively modifying specific regions of the Lipid A structure. The monosaccharide core retains essential functional groups (phosphate, hydroxyl) for receptor interaction, while the fatty acid chains are simplified to necessary lengths and configurations. This localized optimization maintains antagonistic activity at the critical binding interface while reducing overall molecular complexity.
2Reliability
If current treatments for septic shock are used, then some level of LPS signaling antagonism is achieved, but inflammatory cascades are activated
Solution Approach 1:
The simplified Lipid A analogs are designed to preemptively block LPS signaling at the receptor level before inflammatory cascade activation can occur. By competing for binding at the LPS receptor complex (CD14/TLR4), these analogs prevent the conformational changes and downstream signaling events that would otherwise trigger the harmful inflammatory response, thereby providing protective anti-action before the harmful cascade begins.
3Ease of manufacture
If Lipid A analogs with simplified structure are developed, then ease of synthesis improves, but maintaining potent antagonistic activity becomes difficult
Solution Approach 1:
The patent systematically varies key structural parameters of the Lipid A analogs, including fatty acid chain length (C12-C24), chain saturation, and attachment positions on the monosaccharide core. By optimizing these parameters, the patent identifies specific configurations that maintain potent antagonistic activity while significantly simplifying the molecular structure and facilitating easier synthesis compared to the complex natural Lipid A structure.
Data Source
AI summary
The invention provides a series of novel Lipid A analogs that are structually simple, synthetically accessible, and capable of blocking the cellular receptor within the signal transduction pathway. The novel Lipid A analogs can include a monosaccharide core with hydrophobic side chains and amino acid ionic motif. The invention further provides methods of using the compounds and compositions thereof in various therapeutic methods.